Hepatitis A infection: A seroepidemiological study in young adults in North-East Italy
- 26 Downloads
During the period from January to May 1994, the prevalence of antibodies to hepatitis A virus infection (anti-HAV) was tested by immunoenzyme assay in the serum samples of 620 apparently healthy subjects (81% males, 19% females), from 10 to 29 years old, resident in North-East Italy (Pordenone and surrounding district). The overall prevalence of anti-HAV was 3.7%. There was a significant lower prevalence in the group aged 10-19 than in the one aged 20–29 years (0.7% vs 6%; p < 0.001). Moreover, a significant sex difference was observed for the 20–29 year age group (p < 0.001). Among the various risk factors considered, family size and travelling abroad to endemic areas were significantly associated with HAV infection. Since a valid and effective vaccine against HAV infection has recently become available, anti-HAV vaccination campaigns can feasibly be programmed. However, different geographical regions present different epidemiological situations, so its use should be adapted to each region, with special attention to the cost-effectiveness of the immunisation programme. Our data suggest that in our region such vaccination could initially be proposed to high-risk subjects such as those travelling to endemic areas.
Unable to display preview. Download preview PDF.
- 1.Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection. J Hepatol 1993; 18(Suppl 2): S11–S14.Google Scholar
- 2.Mele A, Catapano R, Cialdea L, Marzolini A, Stroffolini T. SEIEVA. Dieci anni di attività del sistema di sorveglianza dell'epatite virale acuta. Notiziario Istituto Superiore di Sanità 1995; 8(S2): 1–4.Google Scholar
- 3.Stroffolini T, Chiaramonte M, Franco E, Rapicetta M, De Mattia D, Mura I, Trivello R, Giammanco A, Rigo G, Scarpa B. Baseline seroepidemiology of hepatitis A virus infection among children and teenagers in Italy. Infection 1991; 19: 97–100.Google Scholar
- 4.Tilzey AY, Banatvala JE. Hepatitis A. Changing prevalence and possible vaccine. Br Med J 1991; 302: 1552–1553.Google Scholar
- 5.Papaevangelou G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine 1992; 10(S1): 63–66.Google Scholar
- 6.Deinhardt F. Prevention of viral hepatitis A: Past, present and future. Vaccine 1992; 10(S1): 10–14.Google Scholar
- 7.Forbes A, Williams R. Changing epidemiology and clinical aspects of hepatitis A. Brit Med Bull 1990; 46: 303–318.Google Scholar
- 8.Chiaramonte M, Moschen ME, Stroffolini T, Rapicetta M, Bertin T, Renzulli G, Ngatchu T, Chionne P, Trivello R, Naccarato R. Changing epidemiology of hepatitis A virus (HAV) infection: A comparative seroepidemiological study (1979 vs. 1989) in North-East Italy. Ital J Gastroenterol 1991; 23: 344–346.Google Scholar
- 9.Angelillo IF, Nobile CGA, Talarico F, Pavia M. Prevalence of hepatitis A antibodies in food handlers in Italy. Infection 1996; 24: 147–150.Google Scholar
- 10.Memoranda/Memorandums. Public health control of hepatitis A: Memorandum from a WHO meeting. Bull WHO 1995; 73: 15–20.Google Scholar
- 11.Mele A. Anti-hepatitis A virus (HAV) vaccination: Guidelines for an immunization strategy in Italy. Workshop Consensus Conference — Rome, May 2–3, 1995. Ital J Gastroenterol 1996; 28: 181–184.Google Scholar